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Abstract
The present research was carried out aiming to assess the hematological
response of dogs with visceral leishmaniasis submitted to treatment.
For this, seven animals naturally infected by Leishmania sp.  were
submitted to a treatment with 75 mg/kg meglumine antimoniate
subcutaneously, 12-12h / 3 weeks. In all animals, a complete blood
count and bone marrow aspiration biopsy were carried out for a
descriptive evaluation at up to seven moments: before the treatment,
30, 60, 90, 120, 150 and 180 days after the start of the treatment.
Before the beginning of the experiment hematological alterations
were observed in four of  the seven dogs (57.1%), among them,
nonregenerative anemia, lymphopenia, lymphocytosis and
monocytosis. During the course of the experiment the occurrence of
leukocytoses, such as left shift neutrophilia and eosinophilia, were
observed in some of  the animals. Before the beginning of  the
treatment (M1), the occurrence of erythrocytic hypoplasia was detected
by bone marrow cytology in two of the dogs (28.6%). This was
reversed through an increase in the amount of erythroid progenitor
cells after the administration of meglumine antimoniate. Thus, it can
be concluded that the treatment led to normalization of the






Visceral leishmaniasis is a disease
caused by a protozoan belonging to the
order Kinetoplastida, family Trypanosomatidae
and genus Leishmania.1,2,3 In the Americas the
etiological agent is Leishmania (Leishmania)
chagasi.1,2,4 The infection usually causes a
chronic systemic disease. However,
depending on the properties of the parasite
and on the immune competence of the host,
the evolution may be acute and severe,
leading the animal to death in a few weeks.5,6
The clinical manifestations of the disease in
dogs and humans are similar and include
fever for long periods, anemia, progressive
loss of weight and cachexia in its final stage.7
In the lymphoid organs, the proliferation of
B lymphocytes, plasmocytes, histiocytes and
macrophages may result in generalized
lymphadenomegaly and hepatosplenomegaly.5,8,9,10
Dermatological alterations are very
frequent in animals with visceral leishmaniasis
and they may occur in the absence of other
symptoms.10 The buildup of  immune
complexes in the kidneys occasionally  results
in proliferative glomerulonephritis and, in
many cases, in interstitial nephritis, which can
lead to kidney insufficiency.3,8,9,11,12,13,14,15
Leishmania also multiply within macrophages
in the liver, producing an active chronic
hepatitis and, occasionally, hepatomegaly,
vomiting, polyuria, polydipsia, anorexia and
weight loss.3,8,11,13,16 Some animals present
chronic diarrhea and melena due to the
presence of ulcerations in the gastric and
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intestinal mucosa. Enteritis may be a result
of direct parasitic damage 11 or a
consequence of kidney insufficiency8,9,17. It
is possible to observe animals with
locomotor, respiratory, cardiac, ophthalmic
and neurologic alterations.11
Dogs with leishmaniasis may present
hemorrhagic diatheses such as hematuria,
petechia, suffusions, and mainly, epistaxis.
Besides the occurrence of ulcerations in the
nasal cavity, other causes for the occurrence
of hemorrhages include vasculitis, uremia,
splenic sequestration of platelets and,
occasionally, thrombocytopenia due to
aplasia or bone marrow hypoplasia.2,11,18,19,20
Pentavalent antimonials, particularly
meglumine antimoniate, are the medications
of choice in the treatment of human visceral
leishmaniasis, and have been used as treatment
protocol for dogs.21 The mechanism of
action of these medications have not been
completely established, but it is known that
they act on the amastigote forms of  the
parasite, blocking their metabolism by
inhibiting the glycolitic activity and the
oxidation pathway of fatty acids, being, thus,
considered leishmanicidal.1,21 Pentavalent
antimonials cause reduction of the
symptoms and, in some cases, even clinical
cure of  the dogs.22,23,24,25,26
The occurrence of blood alterations
in dogs with visceral leishmaniasis is very
important and frequent. The erythrogram
shows anemia, generally normocytic
normochromic nonregenerative in 57 to
94.2% of  the animals.2,8,9,27 Anemia in visceral
leishmaniasis results from several causes,
among them splenic sequestration of red
blood cells, decrease in bone marrow
production, chronic renal failure, blood loss,
hemolysis and immune-mediated
mechanisms.2,9,27,28,29
With regards to the alterations present
in the leukocyte series, some authors report
normal total leukocyte count 8, others
describe the presence of leukocytosis
associated to neutrophilia 30, while others
report the occurrence of leucopenia 10,31.
There are discrepancies in the literature
concerning the occurrence of lymphocytosis
or lymphopenia in dogs with visceral
leishmaniasis. Bourdoiseau et al. 32 carried out
a study comparing the lymphocytic
abnormalities of  seropositive dogs with a
mild clinical picture, with a severe clinical
picture and seronegative dogs and concluded
that the seropositive animals with a good
clinical status presented lymphocytosis,
whereas those with a severe clinical picture
presented lymphopenia. On the other hand,
Ikeda et al.27, in a retrospective study on the
hematological alterations of 191 dogs
naturally infected by Leishmania (L.) chagasi,
observed that lymphocytosis as well as
lymphopenia occurred in animals regardless
of  the severity of  their clinical pictures.
Furthermore, the observation of
monocytosis is common 27,33,34, and it can be
accompanied by the presence of large
activated monocytes 27.
Animals with visceral leishmaniasis
may present normal platelet counts or
thrombocytopenia.2,10,12 The possible causes
for thrombocytopenia are the formation of
self-antibodies, splenic sequestration and
bone marrow suppression.8,10,35
Despite the scarce literature
concerning bone marrow cytology of  dogs
with visceral leishmaniasis, the occurrence of
hyperplasia of precursors of neutrophilic
granulocytes has been reported, thus
enhancing the myeloid:erythroid relation
(M:E). An increase in the population of
monocytes and macrophages and the
elevation in the number of plasmocytes and
Mott cells also occur, which may indicate
antigenic stimulation associated to
infection.30,33,34
Hence, the present study aimed to
verify the hematological response of dogs
with visceral leishmaniasis submitted to a
treatment with meglumine antimoniate.
Material and Method
Seven pet dogs naturally infected by
Leishmania sp., four of them male and three
females, of varied breeds and with ages
ranging from seven to sixty months, were
used. The diagnosis of the disease was
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reached by the identification of amastigote
forms of  Leishmania sp.in the cytological
examination of lymph node and bone
marrow aspirates and confirmed by enzyme
immune assay (ELISA). The serum samples
collected from these dogs were screened to
rule out the possibility of co-infection with
Ehrlichia canis e Babesia canis. The indirect
immunofluorescent antibody test was
performed to detect antibodies to B. canis,
following the protocol described by
Machado36, and an enzyme immunoassay
test (SNAP*3Dx*-IDDEX Laboratories)
for the detection of  E. canis antibodies.
Before the beginning of the experiment the
animals were dewormed with a
combination of praziquantel, pyrantel
palmoate and febantel.  During the whole
experimental period the dogs were fed with
balanced commercial dog food (Selection
Special Croc Evolution® - Royal Canin),
were given water ad libitum, wore
deltamethrin antiparasitic collar (Scalibor® -
Intervet Production S.A.), and were kept in
a screened kennel to avoid reinfection.
The dogs were submitted to a
treatment with 75 mg/kg meglumine
antimoniate (Glucantime® - Aventis Pharma
Ltda) subcutaneously, 12-12h / 3 weeks. A
complete blood count (erythrogram,
leukogram and qualitative platelet count) and
a descriptive myelogram were carried out
at seven moments: M1- before the beginning
of the treatment; M2- 30 days; M3- 60 days;
M4- 90 days; M5- 120 days; M6- 150 days
and M7- 180 days after the beginning of
the treatment.
The total cell count was carried out
by an automated blood cell counter (Celm
– CC510). Hemoglobin determination was
carried out by the hemiglobincyanide
method (CELM E – 205D
spectrophotometry) and packed cell volume
by the microhematocrit method (SIGMA
1-13 microhematocrit centrifuge). The
calculation of hematimetric indices was
carried out according to Jain 37. The
differential count of 100 leukocytes and the
morphological and qualitative evaluation of
the platelets were processed in smears stained
with quick hematological stain, according to
Jain’s recommendations and criteria. 38 The
bone marrow was collected with an
aspiration biopsy needle (Monoject®),
through a puncture on in the iliac crest of
the animals. Immediately after puncturing five
smears were prepared for each animal. The
slides were stained with hematological stain
(Panótico Rápido® – Laborclin – Curitiba,
PR) and observed under an optical
microscope with 100 times magnification for
descriptive evaluation. In cell differentiation,
Harvey’s classification was used. 39 In
compliance with the recommendations of
the Brazilian Ministry of Health, after the 180
days of  follow-up, the dogs were submitted
to euthanasia with 15 mg/kg intravenous
sodium pentobarbital (Hypnol 3% -
Fontoveter – Itapira, SP), followed by an
ampule of 10 mL potassium chloride
(Cloreto de potássio a 19,1% - Darrow –
Rio de Janeiro, RJ).
Results, Discussion and Conclusion
The haemathological analysis of the
seven dogs area summarized in table 1. Four
animals (57.1%) presented anemia, verified
by the decrease in the number of
erythrocytes, hematocrit and hemoglobin,
before and 30 days after the beginning of
the treatment (M1 e M2). M.C.V. and
M.C.H.C. indices were within the normal
range described by Jain37 at all moments,
characterizing an anemia of  the normocytic
normochromic type, which corroborates the
descriptions of Abranches et al.31, Ciaramella
et al.12, Koutinas et al. 9 and Ikeda et al.27,
who reported that this type of anemia is the
most frequent in the cases of visceral
leishmaniasis. Another reason for anemia was
ruled out by means of serological methods
and by cytological examination of bone
marrow smears. In general, the values of  the
erythrocytic series increased after the
treatment, with the disappearance of the
anemic picture between sixty and ninety days
after the beginning of the treatment (M3 e
M4). However, one dog (14.3%) presented
anemia again 120 and 180 days after the
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beginning of the treatment. At 120 days the
identification of  the etiology was not
possible, as the animal did not present any
clinical alteration. At 180 days, however,
amastigote forms of  the parasite were
detected through lymph node and bone
marrow aspiration biopsy and liver and
spleen imprint, which explains the anemic
picture as a result of the multiplication of
the parasite in several organs, including in
the bone marrow.
Before the beginning of the treatment
erythrocytic hypoplasia was observed  in the
bone marrow cytology of  two of  the dogs
(28.6%), which agrees with the findings of
Anosa and Idowu30, Yamaguchi et al.34 and
Buracco et al.33, who reported that animals
with visceral leishmaniasis presented bone
marrow hypoplasia, and also with the
reports of Kontos and Koutinas8, Koutinas
et al.9, Ciaramella and Corona 2 and Ikeda et
al.27, who affirmed that the anemia in dogs
with visceral leishmaniasis is nonregenerative.
After the administration of meglumine
antimoniate, all of the anemic animals
presented a regenerative erythrocytic
response, evidenced by an increase in the
number of erythroid progenitor cells in the
bone marrow, and by the presence of
polychromatophilia, polychromatic
rubricytes and metarubricytes in the
peripheral blood.
Of the seven dogs, two (28.6%)
presented leukopenia, whereas the other five
(71.4%) had normal leukocyte count in the
first evaluation. Such observations disagree
with Abranches et al.31, who observed
leukopenia in 100% of the dogs studied, and
corroborate the reports of Kontos and
Koutinas8 who affirmed that the occurrence
of alterations in the number of leukocytes
in dogs with visceral leishmaniasis is rare.
Thirty days after the beginning of the
treatment three animals (42.9%) presented
leukocytosis due to left shift neutrophilia,
associated to the presence of crepitant rale
in lung fields, indicating pneumonia, which
was confirmed by radiographic examination.
In humans, pentavalent medications may
provoke disturbances in several organs,
among them, the lungs.40 Nonetheless, such
observations have not been described so far
in veterinary medicine literature. Two dogs
(28.6%) presented eosinophilia associated to
leukocytosis due to neutrophilia, probably
resulting from the pulmonary picture.
Besides these, another animal presented
eosinophilia 30 days after the beginning of
Table 1 - Haemathological analysis before the beginning of the treatment (M1),  30 days (M2), 60 days (M3), 90
days (M4), 120 days (M5), 150 days (M6) and 180 days (M7) after the beginning of the treatment.
Araçatuba- SP, 2008
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the treatment (M2), which was associated to
an allergic reaction to a deltamethrin collar.
The occurrence of eosinophilia is common
in alterations of tissues containing a great
amount of mastocytes, such as the skin and
the lungs.41
During the experiment four dogs
(57.1%) presented lymphopenia that could not
be related to the severity of the clinical picture,
since other animals with a similar clinical picture
had lymphocyte count within the normal limits.
Although all animals presented monocyte count
within the normal limits in the beginning of
the experiment, one animal presented
monocytosis 180 days after the beginning of
the treatment (M7), when amastigote forms
of the parasite were evidenced again by the
lymph node and bone marrow aspiration
biopsies.  When the first blood count was
performed, one of  the dogs (14.3%) presented
a normal leukogram, but with the presence
of  activated monocytes.
Before the beginning of the experiment
two animals (28.6%) presented granulocytic
hypoplasia in the bone marrow cytology,
associated to leukopenia in the blood count,
and in the course of the experiment, three dogs
presented granulocytic hyperplasia, with
leukocytosis in the blood count. An increase in
the number of macrophages and monocytes
shown by bone marrow cytology was not
observed in any of  the animals, which disagrees
with the findings of Anosa and Idowu30,
Yamaguchi et al.34 and Buracco et al.33, who
stated that an increase in the number of
monocytes and macrophages is very frequent
in dogs with visceral leishmaniasis. In the course
of the experiment one of the alterations
observed through the myelogram was the
occurrence of plasmocytosis in two dogs,
probably due to the antigenic stimulation
provoked by the infection.30,33,34 No animal
presented alterations in the values of fibrinogen
determination or in the qualitative platelet count,
which disagrees with the reports of Slappendel
and Ferrer10, who verified the occurrence of
thrombocytopenia in 50% of the animals
studied.
Thus, it can be concluded that the
treatment promoted normalization of  the
hematological alterations and recovery of the
bone marrow. Nevertheless, as the treatment
was not able to promote parasitological healing,
in some of the animals the hematological
abnormalities reappeared.
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Avaliação hematológica de cães naturalmente infectados por Leishmania
(Leishmania) chagasi submetidos a tratamento com antimoniato de
meglumina
Resumo
A presente pesquisa foi realizada com o objetivo de avaliar a resposta
hematológica de cães com leishmaniose visceral submetidos a
tratamento. Para tanto, sete animais naturalmente infectados por
Leishmania sp. foram submetidos a um tratamento com 75 mg/kg  de
antimoniato de meglumina por via subcutânea, 12-12 h /3 semanas.
Em todos os animais, uma contagem hematológica completa e punção
biópsia aspirativa de medula óssea foi realizada para uma avaliação
descritiva em até sete momentos: antes do tratamento, 30, 60, 90,
120, 150 e 180 dias após o início do tratamento. Antes do início do
experimento foram observadas alterações hematológicas em quatro
dos sete cães (57,1%), entre eles, anemia não regenerativa, linfopenia,
linfocitose e monocitose. Durante o curso do experimento a ocorrência
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foram observadas em alguns dos animais. Antes do início do
tratamento (M1), a ocorrência de hipoplasia da série eritrocítica foi
detectada pela citologia de medula óssea em dois animais (28,6%).
Isto foi revertido por um aumento na quantidade de células eritróides
progenitoras após a administração de antimoniato de meglumina.
Desta forma, pode-se concluir que o tratamento promoveu a
normalização das alterações hematológicas e recuperação da medula
óssea.
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